National Molecular Pathology Platform

Principal Investigator(s):

    Philipp Lange and Liana Nobre

Over the last ten years, the accessibility of sequencing platforms has advanced from research tools to assays that are now suitable for routine use to guide clinical decisions. In fact, patients with targetable tumours have already shown dramatic responses to molecularly targeted therapy. Prior research studies have demonstrated feasibility and have provided the foundational data to support their incorporation into clinical practice – thus far, primarily in patients with ‘hard to cure’ cancers. However, there remains significant unexplored potential in other advanced molecular diagnostics, including circulating tumour DNA (ctDNA), biofluid and tissue proteomics, and DNA and protein modifications, to further refine disease classification and treatment.

The National Molecular Pathology Platform project aims to identify and advance the next generation of molecular assays to accelerate their translation from research tools to widespread clinical use.

Key Activities :

  • Advance assays with potential for broad clinical utility into routine care by:

    • Accelerating and harmonizing implementation of liquid biopsy testing for all children in which a diagnostic benefit can be demonstrated.
    • Promoting the collection of liquid and tissue biopsies from all patients at the time of a clinically necessary procedure; and
    • Incorporating timely and consistent proteome evidence into routine treatment decision making by operating two National Pediatric Proteome Centres.

  • Democratize access to advanced molecular assays by establishing a National Molecular Pathology Board that will discuss and identify the optimal assays for each referred case.

In line with the principles of equity, diversity and inclusion, this project’s activities also emphasize accessibility by smaller health centres and rural communities. The project will, therefore, address gaps in the equitable access to the latest advancements in molecular pathology and advance diagnostics, to ultimately improve outcomes for all children with cancer in Canada.

For more information, please contact Emily Nakada.

Principal Investigator(s):

    Philipp Lange and Liana Nobre